Genomic Health to Present at Two Upcoming Investor Conferences

REDWOOD CITY, Calif., May 29, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the following conferences in June:

• Kim Popovits, Genomic Health's Chairman, Chief Executive Officer and President, will present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5 at 4:00 p.m. ET in New York City; and
• Dean Schorno, Genomic Health's Chief Financial Officer, will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June 5 at 10:40 a.m. PT in Palos Verdes, Calif.

To access the live and subsequently archived webcast of the presentations, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the beginning of the presentations to allow for any necessary software downloads. Archived replays will be available for three months beginning 24 hours after the live presentations.

About Genomic Health

Forward Looking Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our ability to generate similar results in further studies; the ability of any tests the company may develop to optimize cancer treatment; the ability of the company to develop additional tests in the future; the applicability of clinical study results to actual outcomes; our ability to develop and launch a test for prostate cancer in 2013;   the scope, success or results of clinical trials and the timing of such activities; and the ability of the company's tests to impact clinical practice. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of our tests; the risks associated with competition; the applicability of clinical study results to actual outcomes; the risks associated with the commercialization of current and future products; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 30, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.